UAE Approves Foundayo for Type 2 Diabetes Treatment

Nov 6, 2026

55 min

Nov 6, 2026 15:32

UAE becomes third country globally to approve Foundayo for type 2 diabetes

## UAE's New Approval for Diabetes Medication

The United Arab Emirates has become the third nation globally to authorize the use of Foundayo, an oral medication for managing type 2 diabetes in adults. This approval was granted by the Emirates Drug Establishment (EDE), marking a significant step in expanding treatment options for diabetes patients.

## About Foundayo

Developed by Eli Lilly, Foundayo is a non-peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to be taken once daily without any dietary restrictions. The medication aids in controlling blood sugar levels and supports long-term weight management when combined with a healthy diet and exercise regimen.

## Strategic Objectives

The EDE's decision aligns with its goals to enhance the pharmaceutical regulatory framework by ensuring efficiency and adherence to international standards. This move aims to increase access to innovative treatments and improve chronic disease management.

## Importance of Diabetes Management

The EDE emphasized the need for regular screening and medical follow-up to manage type 2 diabetes effectively and prevent complications. Recognizing risk factors and early detection are crucial in reducing the disease's long-term impact.

Read the full story at the source

What you need to know to get Emirates ID?

Leave your details and get a guide as a gift to avoid mistakes

Article contents

LinkedIn X Facebook WhatsApp Telegram